EMEA-001526-PIP01-13-M05 - paediatric investigation plan

Recombinant parathyroid hormone

Key facts

• Invented name:
  • Natpar
  • Natpar
• Active Substance:
  Recombinant parathyroid hormone
• Therapeutic area:
  Endocrinology-Gynaecology-Fertility-Metabolism
• Decision number:
  P/0369/2021
• PIP number:
  EMEA-001526-PIP01-13-M05
• Pharmaceutical form(s):
  Powder and solvent for solution for injection
• Condition(s) / indication(s):
  Treatment of hypoparathyroidism
• Route(s) of administration:
  Subcutaneous use
• Contact for public enquiries:

  Takeda Pharmaceuticals International AG Ireland Branch

  E-mail: [e-mail]; Tel: [phone]

• Decision type:
  PM: decision on the application for modification of an agreed PIP
• Decision date:
  08/09/2021

Decision

P/0369/2021 : EMA decision of 8 September 2021 on the acceptance of a modification of an agreed paediatric investigation plan for recombinant parathyroid hormone (Natpar), (EMEA-001526-PIP01-13-M05)

AdoptedReference Number: EMA/440401/2021